Presentation is loading. Please wait.

Presentation is loading. Please wait.

Live attenuated influenza vaccine (LAIV) for pigs Hyun Mi, Pyo April, 2014.

Published byMarilynn Maxwell Modified over 7 years ago

Similar presentations

Presentation on theme: "Live attenuated influenza vaccine (LAIV) for pigs Hyun Mi, Pyo April, 2014."— Presentation transcript:

1 Live attenuated influenza vaccine (LAIV) for pigs Hyun Mi, Pyo April, 2014

2 1. Influenza A virus 2. Influenza vaccine 3. Live Attenuated Influenza Vaccine 4. LAIV SIV/606 Contents

3 Influenza A virus Emerging Infectious Disease (2012) Kessell A. et. al. Orthomyxoviridae

4 Influenza A virus CDC, Public Health Image Library, ID#8243 1918, Spanish Flu 2009 Pandemic H1N1, Yoshihiro Kawaoka Courtesy of Yoshihiro Kawaoka, University of Wisconsin-Madison 100nm

5 Influenza A virus ViralZone:www.expasy.org/viralzone, Swiss Institute of Bioinformatics

6 Influenza A virus from healthmediconline.com H3N8

7 Influenza vaccine http://www.who.int/influenza/vaccines/virus/recommendations/en/

8 http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/index-eng.php#tab2

9 Live attenuated influenza vaccine (LAIV) Currently available LAIV - Human: FluMist (intranasal live influeza vaccine, MedImmune) - Equine: attenuated, cold adapted live equine 2 influenza virus live canaripox vector expressing HA of H3N8 Advantages compare to killed/split influenza vaccine - induce strong and long lived immunity - feasible administration route - provide cross protective immunity Disadvantages - Possibility of reversion to virulence or reassortant - Restricted usage in healthy individuals - Maintenance or storage

10 1. Generation of reassortant LAIV from Attenuated donor Clin Exp Vaccin Res 2012;1:35-49 Classical attenuation method Cold-adaptation

11 2. Genetically modified recombinant viruses Modification of HA cleavage site - Stech et al., Nat Med 2005;11:683-9 - Masic et al., J Virol 2009; 83:10198-210 - Replacement of Arg to Val allows HA cleavage by Elastase NS segment truncation mutant - Hai et al., J Virol 2008; 82:10580-90 - Fail to IFN antagonistic function and attenuated in IFN competent systems Mutant virus carrying bivalent HAs - Introduce heterologous HA into one of the segment - Gao et al., J Virol 2010;84 H1N1 carrying 9 segment, H1/H3 - Pena et al., J Virol 2013; 87 H9N2 with H5 in NS segment - Uraki et al., J Virol 2013; 87 H1N1 with H5 in PB2 segment - Masic et al., J Virol 2013; 87 H1N1 with H3 in NA segment

12 Selective packaging model Ozawa and Kawaoka (2011) Virus Research, 162

13 Objectives Produce LAIV candidate Evaluate the attenuation in pigs Efficacy test in pigs - Intratracheal vaccination - Intranasal vaccination

14 A strategy to generate recombinant LAIV candidate HA (Tx98 H3N2) 183nt 157nt19nt 28nt SK02 NA 3’ 5’ TGA NA PA (SIV/SK02) H1-HA (SIV/SK02) PB1 (SIV/SK02) PB2 (SIV/SK02) NP (SIV/SK02) M (SIV/SK02) NS (SIV/SK02) H3-HA (SIV/TX98) A) B) Masic et al., JVIMasic et al., JVI (2013) 87(18):10114-25

15 α-H1 HA α-H3 HA α-M1 C) B) M SIV/TX98 SIV/SK02 SIV-606 D) SIV/TX98SIV/SK02 SIV-606 Mock SK02 TX98 SIV-606 H1 H3 RT-PCR A) α-H1 HA α-H3 HA α-M1 Characterization of H1-H3 rSIV

16 WT SIV/SK02SIV-606 A) B) H1-H3 rSIV growth properties Trypsin+++ NA-+-

17 Pathogenicity study GroupInoculum Concentration (PFU ml -1 ) 1 (n=3)MEM- 2 (n=5)SIV/SK02 (H1N1)10 5 3 (n=5)SIV/SK02 (H1N1)10 6 4 (n=5)SIV/TX98 (H3N2)10 5 5 (n=5)SIV/TX98 (H3N2)10 6 6 (n=5)SIV-606 (H1/H3)10 5 7 (n=5)SIV-606 (H1/H3)10 6 Day 0 Day 5 Virus infection, IT Necropsy Rectal temperature and clinical sign

18 A) B) C) Rectal temperature

19 Gross lesion score in lung 10.2 9.45 6.74 4.4 0.75 1.61

20 Histopathology MEM SIV/SK02 Low dose SIV/SK02 High dose SIV/Tx98 High dose SIV/Tx98 Low dose SIV-606 High dose SIV-606 Low dose B C D E F G

21 Viral titer in lung tissue 5.9E46.5E4 1.8E4 3.7E4 2.4E1

22 Group Vaccination 1 st (day 0) 2 nd (day 21) Challenge (day31) 1 (n=5)MEM SIV/SK02 (H1N1) 2 (n=5)MEM SIV/TX98 (H3N2) 3 (n=5)H1H3 rSIV SIV/SK02 (H1N1) 4 (n=5)H1H3 rSIV SIV/TX98 (H3N2) 5 (n=3)--- Immunoprotection study after IT vaccination Trial 1 Day 0 Day 21 Day 31 Day 36 1 st Vaccination 2 nd Vaccination Necropsy Virus challenge

23 Antigen specific serum IgG titer Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31 A) ** *** B) *** Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31

24 ** Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31 A) *** Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31 B) Antigen specific nasal IgA titer

25 A) B) ** * Rectal temperature after the viral challenge

26 Gross lesion score

27 A) B) C) D) E) Unvaccinated and no viral challenged pig MEM vaccinated andSIV/SK02 challenged pig MEM vaccinated and SIV/Tx98 challenged pig SIV-606 vaccinated and SIV/SK02 challenged pig SIV-606 vaccinated and SIV/Tx98 challenged pig Histopathology

28 Viral titer in lung tissue

29 Group Vaccination 1 st (day 0) 2 nd (day 21) Challenge (day31) 1 (n=5)MEM SIV/SK02 (H1N1) 2 (n=5)H1H3 rSIV SIV/SK02 (H1N1) 3 (n=5)MEM SIV/Tx98 (H3N2) 4 (n=5)H1H3 rSIV SIV/TX98 (H3N2) 5 (n=3)--- Immunoprotection study of Intranasal vaccination Trial 2 Day 0 Day 21 Day 31 Day 36 1 st Vaccination 2 nd Vaccination Necropsy Virus challenge

30 Antigen specific serum IgG titer Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31 Vaccination: MEM SIV-606 MEM SIV-606 MEM SIV-606 Day 0 Day 21 Day 31 A) B)

31 Virus neutralizing antibody titer Day 31Day 36 Day 31Day 36 A) B)

32 Evaluation of protective efficacy A) B) C)

33 A) B) Antigen specific IgG on Day 36

34 Antigen specific IgA on Day 36 A) B)

35 Cell mediate immune response on Day 36 A) B) C) D)

36 Summary 1.A novel LAIV candidate harboring H1 and H3 HAs was generated by rewiring NA segment. 2.LAIV candidate maintained the characteristics of parental virus while having H1 and H3 HAs. 3.Experimental infection of LAIV candidate did not caused any signs of typical SIV infection which indicates attenuation of the virus. 4.Vaccination of LAIV candidate protected the pigs from both parental H1N1 and H3N2 viral challenge. 5.Range of cross protection and vaccine regimen will be further studied.

37 Future study 1.Maternal antibody interference 2.Challenge study in Ferret model

38 Acknowledgement Dr. Yan Zhou Dr. Alexander Masic Animal care staff at VIDO All A121 lab members

39 -Non profit research centre own by U of Saskatchewan - Annual budget $12 million - 160 employees from 20 countries (26 Scientists, 18 PDFs, 34 Technical staff, 44 Grad students, 17 Admin) - 7 Research Programs and two supporting programs : Emerging Disease and Microbial Virulence (BSE, Bacterial Biology & Antimicrobials, influenza, Johne’s disease) Immune modulation Neonatal Immunization Bacterial Vaccine Development (Food Safety, Bovine Mastitis, Mycoplasma) Viral Pathogenesis and Vaccine Development (DNA immunization, HepC,PRRSv) Vectored Vaccines (Bovine and Porcine Adenovirus vectors) Pathogenomics (Pathogenomics of innate immunity, Stress, Disease and Delivery)

40 Chemistry, GMP & Genomics Services Clinical Research & Epidemiology (3 Veterinarians) - Certified Intervac CL3 facility ($140 million) - Attained ISO9001 Certification in 2013

41 Thank you for your attention~

Download ppt "Live attenuated influenza vaccine (LAIV) for pigs Hyun Mi, Pyo April, 2014."

Similar presentations

Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.

Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.
Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian virus Vaccine 2007 Huoying Shi, Xiu Fan Liu, Xiaorong Zhang,

Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian virus Vaccine 2007 Huoying Shi, Xiu Fan Liu, Xiaorong Zhang,
Prevalence of HBV* by Region

Prevalence of HBV* by Region
PANDEMIC INFLUENZA VIRUSES: PAST AND FUTURE PETER PALESE DEPARTMENT OF MICROBIOLOGY MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK ISTANBUL, JULY 11, 2011.

PANDEMIC INFLUENZA VIRUSES: PAST AND FUTURE PETER PALESE DEPARTMENT OF MICROBIOLOGY MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK ISTANBUL, JULY 11, 2011.
Lessons Learned from the Reconstruction of the 1918 Pandemic Adolfo García-Sastre, PhD Professor of Microbiology Mount Sinai School of Medicine.

Lessons Learned from the Reconstruction of the 1918 Pandemic Adolfo García-Sastre, PhD Professor of Microbiology Mount Sinai School of Medicine.
Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.
Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.

Vaccines Robert Beatty MCB150. Passive vs Active Immunity  Passive immunization transfer of antibodies  Vaccines are active immunizations (mimic natural.
Chapter 12-Vaccines Traditional vs. rDNA vaccines Subunit vaccines Peptide vaccines Genetic immunization: DNA vaccines Attenuated vaccines Vector vaccines.

Chapter 12-Vaccines Traditional vs. rDNA vaccines Subunit vaccines Peptide vaccines Genetic immunization: DNA vaccines Attenuated vaccines Vector vaccines.
Seasonal Influenza and Swine-Origin Influenza A (H1N1) Virus

Seasonal Influenza and Swine-Origin Influenza A (H1N1) Virus
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Genetics & Gene Therapy (Ch.30) By: Mahmoud A. El-Hallak Mahmoud A. El-Hallak(120061654) Supervised by: Dr. Abdelraouf A. El manama Dr. Abdelraouf A. El.

Genetics & Gene Therapy (Ch.30) By: Mahmoud A. El-Hallak Mahmoud A. El-Hallak( ) Supervised by: Dr. Abdelraouf A. El manama Dr. Abdelraouf A. El.
Smallpox and Influenza In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.

Smallpox and Influenza "In early 1962 long queues attended any clinic in Birmingham offering vaccination, because three patients with smallpox were in.
Influenza Chapter 39. Causative Agents Influenza A virus Family Orthomyxoviridae Negative-stranded RNA genome Genome divided into 8 gene segments Spiked.

Influenza Chapter 39. Causative Agents Influenza A virus Family Orthomyxoviridae Negative-stranded RNA genome Genome divided into 8 gene segments Spiked.
Vaccination. NATURALLY ACQUIRED IMMUNITY Active: Acquired through contact with microorganisms (infection). Provides long term protection. Passive: Antibodies.

Vaccination. NATURALLY ACQUIRED IMMUNITY Active: Acquired through contact with microorganisms (infection). Provides long term protection. Passive: Antibodies.
Preparation and Evaluation of an Inactivated Multi-Strain PRRS Vaccine Made with Viruses Isolated from Vietnam Central Vietnam Veterinary Institute This.

Preparation and Evaluation of an Inactivated Multi-Strain PRRS Vaccine Made with Viruses Isolated from Vietnam Central Vietnam Veterinary Institute This.
Central Vietnam Veterinary Institute

Central Vietnam Veterinary Institute
Active and passive immunization Immunity to infectious microorganisms: Immunity to infectious microorganisms: 1- Active immunization *** natural processes.

Active and passive immunization Immunity to infectious microorganisms: Immunity to infectious microorganisms: 1- Active immunization *** natural processes.
Influenza Vaccine Development

Influenza Vaccine Development
Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,
Www.altaweb.it/hepacivac The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.

The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.

Similar presentations

Ads by Google